News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AVANOS MEDICAL, INC. (AVNS) filed a Form 15 with the SEC on August 6, 2026, certifying the termination of its registration under Section 12(g) and suspension of its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. …
The article focuses on the "Enterprise value to EBITDA forward" metric for Avanos Medical, Inc. (SWB:8HH) listed on the Stuttgart Stock Exchange. The content is primarily a navigation-heavy page from TradingView, indicating where this specific financial data point can be found on their platform …
Avanos Medical has been acquired by affiliates of American Industrial Partners (AIP) in a going-private transaction valued at approximately $1.272 billion, with shareholders receiving $25.00 per share in cash. Following the acquisition on July 27, 2026, Avanos' common stock ceased trading on the NYSE …
This article from TradingView provides financial information for Avanos Medical, Inc. (SWB:8HH), specifically focusing on its forward price-to-sales ratio. The content appears to be a stub or an incomplete financial data page, as no specific values or analysis are present. It primarily consists of …
Vanguard Capital Management has disclosed a beneficial ownership of 2,344,195 shares, representing a 5% stake in Avanos Medical Inc. This holding grants Vanguard sole voting power over 350,401 shares and sole dispositive power over all 2,344,195 shares. The shares are held by various Vanguard …
This article provides access to the "Price to earnings forward" financial metric for Avanos Medical, Inc. (LSX:A2JNRG) on the TradingView platform. It highlights that no trades occurred for this stock, and the market is currently closed. Users can find detailed financial information, documents, community …
Avanos Medical has finalized new secured credit facilities totaling $775 million in term loans and a $100 million revolving credit facility, set to mature in 2033. These new facilities will support the company's take-private merger and ensure future liquidity, while simultaneously replacing its previous …
Avanos Medical (AVNS) announced on July 27, 2026, its request to the NYSE for a trading suspension and the filing of Form 25 to delist and deregister its common stock following its merger. Trading of its shares was suspended on July 27, 2026. The …
Latham & Watkins LLP advised the financing sources for American Industrial Partners' (AIP) acquisition of Avanos Medical, Inc. for approximately US$1.272 billion. The transaction involved a large legal team from Latham, providing expertise across various areas including capital markets, banking, executive compensation, data transactions, …
Avanos Medical director Patrick J. O’Leary reported the disposition of 54,640 common shares and 12,003 restricted share units on July 27, 2026, as part of a merger. Each share and unit was converted into the right to receive $25.00 in cash, resulting in O'Leary …
Sterlington is advising the management team of Avanos Medical, Inc. on its acquisition by affiliates of investment funds advised by American Industrial Partners (AIP) for approximately $1.27 billion. This transaction expands Sterlington's portfolio of take-private advisory engagements and its health sector involvement. The Sterlington …
Avanos Medical, Inc. generated €597.01 million in revenue last year, with its Specialty Nutrition Systems - Enteral Feeding segment contributing the most at €267.94 million. The majority of this revenue, €463.09 million, originated from North America, though this was a decrease from the previous …
Avanos Medical CEO David Pacitti's equity awards were converted to cash at $25.00 per share due to the merger effective July 27, 2026. This included the disposition of 322,194 common shares and the conversion of 444,730 performance-based RSUs and 239,354 stock options into cash, …
Avanos Medical CFO Scott Michael Galovan reported details on the company's merger, where each common share was converted into $25.00 cash. This transaction involved the exchange of 135,596 shares of common stock, including time-based restricted stock units, for cash. Additionally, 96,121 performance-based restricted stock …
American Industrial Partners (AIP) has completed its acquisition of Avanos Medical (NYSE: AVNS) for approximately $1.272 billion. Avanos stockholders will receive $25.00 in cash per share, and the company's common stock will cease trading on the New York Stock Exchange, making Avanos privately held. …
This press release announces that American Industrial Partners (AIP) has successfully completed its acquisition of Avanos Medical, Inc. The acquisition marks a significant change for Avanos Medical, transitioning it from a publicly traded company to a privately held entity under AIP's ownership. The move …
Avanos Medical, Inc. (AVNS) has filed a Form 25-NSE with the SEC to voluntarily delist its common stock from the New York Stock Exchange. This action is being taken under Section 12(b) of the Securities Exchange Act of 1934 and 17 CFR 240.12d2-2(c), which …
Avanos Medical, Inc. (AVNS) has been removed from the S&P Healthcare Equipment Select Industry Index. This follows several other recent index removals, including various Russell indices. Avanos Medical is a medical technology company focused on delivering medical device solutions for nutrition, pain management, and …
This article provides a stock forecast for Avanos Medical, Inc. (AVNS), a U.S.-based medical device company. An Argus research report, dated July 1, 2026, rates the company and includes a current price of $24.99, urging users to upgrade for full access to the report …
Avanos Medical Inc (AVNS) is trading at $24.990 with a slight increase of +0.04%. The company's fundamentals are robust with high growth potential, and its valuation is considered fairly valued within the Healthcare Equipment & Supplies industry. Analysts currently rate the stock as "Hold" …
Avanos Medical (AVNS) has seen a sharp rebound in its share price, with a 123.43% year-to-date return, despite reporting a net loss of $74.4 million on revenues of $715.9 million. The company currently trades at a price-to-sales (P/S) ratio of 1.6x, considered overvalued compared …
Avanos Medical stockholders have officially approved the acquisition of the company by American Industrial Partners. This news was reported by Reuters and is available through Refinitiv. Interested parties can access further details via a free trial.
Avanos Medical stockholders have approved the acquisition by American Industrial Partners (AIP) for $25.00 cash per share, with approximately 99.75% of votes cast in favor. All necessary regulatory approvals have been secured, and the transaction is anticipated to close no later than July 27, …
Avanos Medical Inc. (AVNS) is demonstrating a steady performance in its medical devices sector, emphasizing improved operating margins and stronger free cash flow. Despite a slight revenue decline due to divestments and currency effects, the company's strategic focus on profitability, efficiency, and higher-margin product …
* S&P Dow Jones Indices announced on Monday the latest changes [https://seekingalpha.com/pr/20588716-krystal-biotech-set-to-join-s-and-p-midcap-400-tutor-perini-and-v2x-to-join-s-and-p-smallcap] to its U.S. equity indexes, with merger activity driving several constituent replacements. * Krystal Biotech (KRYS [https://seekingalpha.com/symbol/KRYS]) will join the S&P MidCap 400, replacing Taylor Morrison Home (TMHC [https://seekingalpha.com/symbol/TMHC]) before trading opens …
Københavns Lufthavne A/S It is with profound sadness that Copenhagen Airports A/S announces that its Chief Financial Officer, Rasmus Lund, passed away unexpectedly from a heart attack during the night. Rasmus Lund was a highly valued colleague and member of the Executive Management team. …
This article analyzes Avanos Medical Inc. (NASDAQ: AVNS), identifying a neutral near- and mid-term outlook that could moderate a long-term positive bias. It highlights a significant short setup with an exceptional 42.0:1
Avanos Medical (AVNS) has filed a proxy statement detailing a merger agreement from April 13, 2026, which will make the company a wholly-owned subsidiary of a parent entity. A special shareholder meeting is set for July 22, 2026, to vote on the merger, advisory …
Search by ticker symbol or company name and select a result to open its chart.